Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Langenau – page 35

649 clinical trials in Langenau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Langenau at a glance
649
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

649 trials in Langenau

Open in trial search

Cholangiocarcinoma

Not recruiting

Study of Ivosidenib, Durvalumab, and Gemcitabine/Cisplatin for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Migraine

Not recruiting

Study on Atogepant for Preventing Menstrual Migraine in Women

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 1 diabetes mellitus

Not recruiting

Study on Verapamil SR for Adults with Newly Diagnosed Type 1 Diabetes to Preserve Beta-Cell Function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Verapamil Hydrochloride
  • Sponsor:Medical University Of Graz

Bladder transitional cell carcinoma

Not recruiting

Study of Eciskafusp Alfa and BCG for Patients with High-Risk Bladder Cancer Not Responding to BCG Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RO7284755
  • Sponsor:F. Hoffmann-La Roche AG

Epilepsy

Not recruiting

Study on the Effectiveness and Safety of Levetiracetam XR for Patients with Drug-Resistant Partial Onset Epilepsy

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Levetiracetam
  • Sponsor:Neuraxpharm Pharmaceuticals S.L.

Oropharyngeal squamous cell carcinoma

Not recruiting

Study on Reducing Treatment Intensity for Patients with HPV-Positive Oropharyngeal Cancer Using Cisplatin and Carboplatin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Cardiff University

Primary mediastinal large B-cell lymphoma

Not recruiting

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Axicabtagene Ciloleucel
  • Sponsor:Universitaet Muenster

Crohn's disease

Not recruiting

Study on the Safety and Effects of ORG-129 in Patients with Fibrostenotic Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Colorectal cancer metastatic+2

Not recruiting

Study on Methadone Hydrochloride and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:AIO-Studien gGmbH

Chronic myeloid leukaemia (in remission)

Not recruiting

Study on Stopping Nilotinib for Chronic Myeloid Leukemia Patients After Previous Unsuccessful Attempts to Stop Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Heidelberg University

Breast cancer+4

Not recruiting

Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Institut Für Frauengesundheit GmbH

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Langenau

What the registry says about research in the country

01 Inflammatory Skin Conditions

Clinical research focusing on plaque psoriasis and psoriatic arthritis, evaluating novel therapeutic approaches for both biologic-naive and experienced patients. Studies aim to assess treatment efficacy in reducing disease symptoms and improving patient outcomes.

  • Moderate to Severe Plaque Psoriasis
  • Active Psoriatic Arthritis
  • Long-term Safety Studies

Multiple investigations are comparing new therapeutic agents against placebo and established treatments.

02 Chronic Skin Disorders

Comprehensive studies addressing hidradenitis suppurativa and atopic dermatitis. Research focuses on evaluating new treatments for these challenging conditions, with emphasis on both immediate efficacy and long-term management.

  • Hidradenitis Suppurativa Management
  • Atopic Dermatitis Treatments
  • Novel Therapeutic Approaches

Trials are examining both topical and systemic treatments for optimal disease control.

03 Dermatological Conditions

Innovative research addressing various skin conditions including chronic venous ulcers, actinic keratosis, and rosacea. Studies range from stem cell therapies for wound healing to novel topical treatments.

  • Wound Healing Therapies
  • Skin Lesion Treatments
  • Inflammatory Conditions

Research includes both traditional and cutting-edge therapeutic approaches.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.